BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday,

Related news

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TMCITreace Medical Concepts2026-07-24 11:05 EST

Treace to Report Second Quarter 2026 Financial Results on August 7, 2026

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

OMOutset Medical2026-07-23 13:00 EST

Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

SGHTSight Sciences2026-07-22 20:05 EST

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

STXSStereotaxis2026-07-21 13:00 EST

Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

LUNGPulmonx2026-06-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-04-29 20:05 EST

Pulmonx Reports First Quarter 2026 Financial Results

Stock data

Close
2.05 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States